Supriya Lifescience Ltd

Resolutions and outcome

• Resolution: Special; re-appoint Balasaheb Sawant as WTD & KMP for 26 May 2026 to 25 May 2029.
• Result: Special Resolution carried; assent 99.69%, dissent 0.31%.
• Voting details: Remote e-voting from 23 Jul to 21 Aug 2026; total votes polled 58,281,483.
• Record date: Voting entitlements cut-off 17 July 2026; notice dispatched 21 July 2026.

Financial Performance

• Q1 FY'27 revenue: Rs 190 cr, up 31% YoY from Rs 145 cr.
• Q1 FY'27 EBITDA Rs 47 cr; 25% margin; down 8.1% YoY from 52 cr.
• PAT Rs 24 cr; 12.7% margin in Q1 FY'27, vs Rs 35 cr in Q1 FY'26.
• Capex Q1 FY'27: Rs 16.58 cr; maintenance, small projects, Isambe.
• Patalganga Phase-1 CapEx Rs 200 cr; two API blocks, two formulation blocks.
• Closing inventory Rs 230–240 cr as of June 30; plan liquidation over 3–4 quarters.
• Exports contributed 81% of Q1 FY'27 revenue; Asia 39%, Europe 35%, LATAM 20%.
• Backwards integration: 72% of total revenues fully integrated.

Capex & Projects

• Capex Q1 FY'27: Rs 16.58 cr; maintenance capex and Isambe project.
• Patalganga land: Phase-1 CapEx around Rs 200 cr; 2 API blocks, 2 formulation blocks.
• Block F not started; to begin in next two quarters.

Liquidity & Inventory

• Cash reserves around Rs 150 cr in FDs and mutual funds.
• Borrowings for the full year: no working capital limits utilized; LC & bank guarantees used.
• Depreciation: Ambernath ~ Rs 14–15 cr; full-year depreciation ~ Rs 35–40 cr.

Guidance & Outlook

• Trajectory towards Rs 1,000 crores revenue by FY'27 remains firmly on track.
• EBITDA margins guidance 33–35% for FY27.

Q&A Highlights

• Q2 production: phased maintenance; no major Q2 impact.
• Water issue resolved; 15–20 days; Rs 30–35 cr revenue loss.
• Retroactive solar subsidy payment Rs 4.5–5 cr; sub judice.
• EU export authorization obtained; Ambernath shipments to regularize; High Court outcome pending.
• Closing inventory 230–240 cr; plan to liquidate over 3–4 quarters.
• R&D and CDMO focus: SAP go-live in 4–5 months; TrackWise quality software rollout.

Meeting Details

• Date of earnings call: August 14, 2026; time not disclosed.
• Meeting type: earnings call; format: audio recording.
• Key company participant: Company Secretary & Compliance Officer.
• Purpose: discuss operational and financial performance for the quarter ended June 30, 2026.
• Recording: audio recording of the earnings call is available on the company's website.

Key financials and developments

• Revenue Rs 189.75 Cr in Q1 FY27, up 30.8% YoY.
• EBITDA Rs 47.46 Cr; EBITDA margin 25.0% in Q1 FY27.
• PAT Rs 24.04 Cr; PAT margin 12.7% in Q1 FY27.
• Export contribution 81% of Q1 FY27 revenue; Asia 39%, Europe 35% share.
• Anesthetic revenue share 48%; vitamins 17% of Q1 FY27 revenue.
• Capacity utilisation 70%; reactor capacity 932 KLPD; Ambernath facility commissioned; two FY27 launches planned.

Business overview

• Backward-integrated model with 20 products across key therapies.
• Diversified geographic presence with strong export orientation.

Operational highlights

• Reactor capacity expanded to 932 KLPD across facilities.
• Ambernath facility fully commissioned; five finished-dosage lines operational.
• New vitamin product block commissioned; debottlenecking for expansion underway.
• Capacity expansion planned with a new Lote block and a nasal line.
• Two new R&D centers established (Ambernath API, Lote lifecycle).
• CMO/CDMO opportunities and exclusive manufacturing rights under evaluation.
• Regulatory filings in EU and US underway; EU-GMP, COFEPRIS, Health Canada approvals targeted.
• FY27 pipeline targets ~2 launches each in Anesthetic and ADHD.
• Expanded API customer base across Japan, EU, and US.

Financial performance

• Q1 FY27 revenue: INR 1,897.5 Mn.
• EBITDA: INR 474.6 Mn; PAT: INR 240.4 Mn.
• EBITDA margin 25.0%; PAT margin 12.7%.
• Revenue up 30.8% YoY; PAT down 30.9% YoY.

Strategic priorities & outlook

• Pursue capex-led capacity expansion; target new blocks at Lote and expanded lines.
• Capitalize on API and finished-dosage CDMO opportunities.
• Six EU dossiers planned this year; two FY27 launches in Anesthetic and ADHD.
• Maintain diversified export orientation and reduce customer concentration.

Governance & risks

• Key management: CFO Krishna Raghunathan; Executive Chairman Satish Wagh; MD Saloni Wagh; JMD Shivani Wagh.
• Forward-looking statements involve risks; no obligation to update.

Financial highlights (Standalone, Q1 FY27)

• Revenue from operations: 1,897.47 for quarter ended 30-06-2026.
• Total income: 1,923.95 for quarter ended 30-06-2026.
• Total expenses: 1,516.03 for quarter ended 30-06-2026.
• Profit before tax: 407.92 for quarter ended 30-06-2026.
• Current tax: 85.13; Deferred tax: 82.36) for quarter ended 30-06-2026.
• Total comprehensive income: 246.90 for quarter ended 30-06-2026.
• EPS (Basic/Diluted): 2.99 for quarter ended 30-06-2026.
• No subsidiary/associate/joint venture as of 30-06-2026.
• Export shipment recognized as sale due to customs custody.

Meeting Details

• Date and time: Friday, August 14, 2026 at 11:00 AM IST.
• Type and mode: earnings call (group investor call), virtual.
• Event/organiser: Supriya Lifescience Limited.

Participants

• Executive Chairman & WTD.
• Managing Director.
• Chief Financial Officer.

Purpose

• Discuss Q1 FY27 unaudited results for quarter ended June 30, 2026.

Additional Notes

• Investor presentation to be shared with exchanges separately.

Dematerialisation processing and listing

• RTA processed dematerialisation requests for quarter ended 30 June 2026 and confirmed outcomes to depositories.
• Securities dematerialised have been listed on the stock exchanges where the existing securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted as registered owner.